International Journal of Radiation Research

en Patient-derived three-dimensional bioprinted models of low-grade glioma: A pilot feasibility study Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;">Background: Patient-derived three-dimensional (3D) models may improve preclinical research of low-grade gliomas (LGGs), but the feasibility of bioprinting adult LGG tissue is poorly defined. Materials and Methods: Fresh surgical specimens from three patients with CNS WHO grade 2, IDH1-mutant gliomas were mechanically and enzymatically dissociated and incorporated into 7.5% or 8% gelatin methacryloyl bioinks. Constructs personalized to the patient were generated by extrusion bioprinting and cultured under physiological hypoxia for 35 days. Serial bright-field microscopy was used to assess morphological development and structural integrity. Intracellular ATP was measured longitudinally as an indirect marker of viable, metabolically active cells. Results: All three samples were successfully bioprinted into constructs. In the model from patient 1, tumor cells aggregated gradually during early culture and formed compact spheroid- or organoid-like structures by day 6–9. The printed architecture remained visible up to day 35 without apparent macroscopic collapse or total disintegration. In both GelMA formulations, the ATP-associated chemiluminescence in the Patient 1-derived model was not diminished as compared to the baseline at day 3 and remained high throughout the observation period, indicating persistent metabolic viability. The available data did not allow for a definitive comparison between the two concentrations of GelMA, nor for an evaluation of reproducibility across all patients. Conclusion: Patient-derived LGG cells can be encapsulated in 3D bioprinted GelMA constructs and cultured in-vitro for up to 35 days. These findings support technical feasibility and warrant validation in larger cohorts with molecular-fidelity and drug-response analyses.</div> Low-grade glioma, patient-derived organoid, 3D bioprinting, in-vitro model, tumor microenvironment. 969 979 http://ijrr.com/browse.php?a_code=A-10-1-1604&slc_lang=en&sid=1 B. Hu 7900319475328460034755 7900319475328460034755 No Department of Neurosurgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China 2CD BioEng & Therapy Co. Ltd, Ningbo, Zhejiang, China S. Yang 7900319475328460034756 7900319475328460034756 No Department of Neurosurgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China 2CD BioEng & Therapy Co. Ltd, Ningbo, Zhejiang, China Z. Zhang 7900319475328460034757 7900319475328460034757 No CD BioEng & Therapy Co. Ltd, Ningbo, Zhejiang, China Y. Liu 7900319475328460034758 7900319475328460034758 No Department of Neurosurgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China 2CD BioEng & Therapy Co. Ltd, Ningbo, Zhejiang, China D. Jiang yangj583@alumni.sysu.edu.cn 7900319475328460034759 7900319475328460034759 Yes CD BioEng & Therapy Co. Ltd, Ningbo, Zhejiang, China J. Yang jiangdacheng@nb-changdu.com 7900319475328460034760 7900319475328460034760 No Department of oncology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China